Results 171 to 180 of about 1,183,948 (211)

Erythropoietin in Chronic Heart Failure

Congestive Heart Failure, 2007
In patients with chronic heart failure (CHF), anemia is common and is associated with adverse outcome. Correction of anemia by erythropoiesis‐stimulating proteins would thus seem attractive. Endogenous erythropoietin (Epo) levels are increased in CHF and are associated with severity of the disease and with increased mortality.
Anne M S, Belonje, Adriaan A, Voors, Wiek H, van Gilst, Dirk J, van Veldhuisen   +3 more
openaire   +2 more sources

Testosterone in Chronic Heart Failure

2008
Chronic heart failure is common and can be described as a syndrome characterized by impairment of cardiac function associated with a maladaptive metabolic and neurohormonal axis. The thesis that testosterone replacement therapy may be helpful as a treatment for chronic heart failure may seem at first to be unlikely.
C, Malkin, T, Jones, K, Channer
openaire   +2 more sources

Pathophysiology of chronic heart failure

The American Journal of Medicine, 2001
Heart failure is a changing paradigm. The hemodynamic model, which served our needs well from the 1950s through the early 1980s, has now been largely abandoned, except for the management of decompensated patients in the hospital. The pathophysiology is exceedingly complex and involves structural changes, such as loss of myofilaments, apoptosis and ...
openaire   +2 more sources

Bisoprolol in chronic heart failure

Hospital Medicine, 2000
The evidence for the use of beta-blockers in heart failure is substantial. Latest recommendations and guidelines suggest that most heart failure patients should be on a drug regimen of an angiotensin-converting enzyme inhibitor, diuretic and a beta-blocker.
openaire   +2 more sources

Homocysteine in Chronic Heart Failure

Clinical Laboratory, 2015
Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease. Homocysteine (Hcy) can generate reactive oxygen species. Oxidative stress enhances the progression of cardiovascular diseases and has long been implicated in chronic heart failure (CHF).
Pauline, Fournier, Joelle, Fourcade, Jérome, Roncalli, Robert, Salvayre, Michel, Galinier, Elizabeth, Caussé   +5 more
openaire   +2 more sources

[Anemia in chronic heart failure].

Revista clinica espanola, 2011
Anemia is one of the most common comorbidities in patients with decompensated chronic heart failure admitted to the Internal Medicine Ward. However, although there is evidence supporting its treatment to improve the functional capacity of the patients and to reduce the new admissions rate, the clinical practice guidelines do not provide any directives ...
Grau-Amoros, J, Formiga, F, Urrutia, A
openaire   +2 more sources

Management of chronic heart failure

Drugs of Today, 1999
Although chronic heart failure remains a major source of morbidity and mortality, recent advances in treatment have resulted in substantial improvements in survival, quality of life and exercise capacity, while at the same time reducing hospitalizations and overall cost of care.
openaire   +2 more sources

The pathophysiology of chronic heart failure

Perfusion, 2000
Although the reduction in cardiac function is the cause and central abnormality of heart failure, there is clearly a very wide range of abnormalities in other systems that contribute to both the symptoms and progression of the syndrome of CHF. We must be aware of these changes to use the available therapeutic options to maximal effect, as well as being
openaire   +2 more sources

Valsartan in Chronic Heart Failure

Annals of Pharmacotherapy, 2005
OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases were searched (1983–June 2004) using the key words angiotensin-receptor blocker, heart failure, valsartan, Diovan, and angiotensin-converting enzyme inhibitor.
openaire   +2 more sources

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient’s left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure ...
openaire   +2 more sources